

## Special Issue

# MiRNA Targets in Cancer: Diagnosis, Prognosis and Treatment

### Message from the Guest Editor

Over the last decade, miRNAs have become one of the most promising biomarkers in cancer. Numerous studies have shown that these short RNA sequences play a crucial role in the neoplastic process, including cell death regulation, proliferation, signalling, and the formation of metastasis. On the basis of changes in the level of miRNA expression, the detection and differentiation of many pathological conditions, including the development of cancer, are possible. Moreover, miRNAs have been indicated as markers of metastasis, treatment outcome predictors (chemosensitivity, radiosensitivity), and prognostic factors in nearly all types of cancers. However, what is the best strategy to search for miRNAs with the highest predictive value? How many promising results have been validated so far and have the previous results been confirmed? How far are we from using individual miRNAs or complete miRNA profiles in routine clinical practice? With your help, we aim to answer these and many other questions in this Special Issue, entitled MiRNA Targets in Cancer: Diagnosis, Prognosis and Treatment. Research articles and comprehensive reviews are welcome in this Special Issue.

### Guest Editor

Prof. Dr. Radosław Mlak

Body Composition Research Laboratory in the Department of Human Physiology, Medical University of Lublin, Radziwiłłowska 11, 20-080 Lublin, Poland

### Deadline for manuscript submissions

closed (10 February 2023)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/106424](https://mdpi.com/si/106424)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).